These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 16387131)

  • 61. Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C.
    Saab S; Oh MK; Ibrahim AB; Durazo F; Han S; Yersiz H; Farmer DG; Ghobrial RM; Goldstein LI; Tong MJ; Busuttil RW
    Liver Transpl; 2007 Jul; 13(7):1032-8. PubMed ID: 17600345
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Clinical outcome after living donor liver transplantation in patients with hepatitis C virus-associated cirrhosis].
    Park JI; Choi KM; Lee SG; Hwang S; Kim KH; Ahn CS; Moon DB; Chung YH; Lee YS; Suh DJ
    Korean J Hepatol; 2007 Dec; 13(4):543-55. PubMed ID: 18159152
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Development of hepatic granulomas in patients receiving pegylated interferon therapy for recurrent hepatitis C virus post liver transplantation.
    Fiel MI; Shukla D; Saraf N; Xu R; Schiano TD
    Transpl Infect Dis; 2008 Jun; 10(3):184-9. PubMed ID: 17916116
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Antiviral treatment withdrawal in viremic HCV-positive liver transplant patients: impact on viral loads, allograft function and morphology.
    Kornberg A; Küpper B; Tannapfel A; Thrum K; Bärthel E; Settmacher U
    Liver Int; 2006 Sep; 26(7):811-6. PubMed ID: 16911463
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Boceprevir in liver transplant recipients.
    Saab S; Manne V; Bau S; Reynolds JA; Allen R; Goldstein L; Durazo F; El-Kabany M; Han S; Busuttil RW
    Liver Int; 2015 Jan; 35(1):192-7. PubMed ID: 24673728
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Controversies in the management of hepatitis C virus infection after liver transplantation.
    Shiffman ML; Vargas HE; Everson GT
    Liver Transpl; 2003 Nov; 9(11):1129-44. PubMed ID: 14586872
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma.
    Hsu YC; Ho HJ; Wu MS; Lin JT; Wu CY
    Hepatology; 2013 Jul; 58(1):150-7. PubMed ID: 23389758
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Characteristics of hepatitis C treatment with pegylated interferons and ribavirin.
    Jiménez-Méndez R; Castañeda-Hernández G
    Ann Hepatol; 2010; 9 Suppl():61-4. PubMed ID: 20713998
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Nonresponders of interferon/ribavirin treatment for recurrent hepatitis C following liver transplantation.
    Smallwood GA; Davis L; Connor K; Martinez E; Stieber AC; Heffron TG
    Transplant Proc; 2003 Jun; 35(4):1476-7. PubMed ID: 12826197
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Effectiveness of peg-interferon and ribavirin for hepatitis C in a patient with hypertension and diminished kidney function].
    Bátyi E; Szegedi J
    Orv Hetil; 2008 May; 149(19):889-92. PubMed ID: 18450549
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Acute hepatitis B in a patient with OLT during treatment with peg-interferon and ribavirin for hepatitis C recurrence.
    Biliotti E; Zacharia S; Grieco S; Spaziante M; Giusto M; Merli M; Gallinaro V; Taliani G
    J Chemother; 2012 Dec; 24(6):369-72. PubMed ID: 23174103
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Combination therapy of interferon alpha-2B and ribavirin for recurrent hepatitis C after liver transplantation.
    Castedal M; Siewert-Delle A; Olausson M; Friman S
    Transplant Proc; 2003 Mar; 35(2):820-1. PubMed ID: 12644153
    [No Abstract]   [Full Text] [Related]  

  • 73. How can we identify better those with recurrent hepatitis C who will respond to therapy? What are the optimal treatment regimen and treatment duration?
    Wright TL
    Liver Transpl; 2003 Nov; 9(11):S109-13. PubMed ID: 14586905
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Successful treatment with novel triple drug combination consisting of interferon-gamma, interferon alfacon-1, and ribavirin in a nonresponder HCV patient to pegylated interferon therapy.
    Balan V; Rosati MJ; Anderson MH; Rakela J
    Dig Dis Sci; 2006 May; 51(5):956-9. PubMed ID: 16758306
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Emerging strategies for pegylated interferon combination therapy.
    Schiff ER
    Nat Clin Pract Gastroenterol Hepatol; 2007 Jan; 4 Suppl 1():S17-21. PubMed ID: 17235281
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Interferon/pegylated interferon and ribavirin in HCV-associated kidney disease with or without cryoglobulinemia.
    Bruchfeld A; Lindahl K; Stahle L; Schvarcz R
    J Hepatol; 2006 Feb; 44(2):432-3; author reply 433. PubMed ID: 16338023
    [No Abstract]   [Full Text] [Related]  

  • 77. Antiviral maintenance treatment with interferon and ribavirin for recurrent hepatitis C after liver transplantation: pilot study.
    Kornberg A; Küpper B; Tannapfel A; Bärthel E; Thrum K; Settmacher U
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2135-42. PubMed ID: 18031371
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Treatment of hepatitis C in liver transplant recipients.
    Gordon FD; Kwo P; Vargas HE
    Liver Transpl; 2009 Feb; 15(2):126-35. PubMed ID: 19177439
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Management of hepatitis C.
    Smith C
    Minn Med; 2003 Jun; 86(6):53-6. PubMed ID: 12834215
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinicopathological features of hepatitis C virus disease after living donor liver transplantation: relationship with in situ hybridisation data.
    Masuda Y; Nakazawa Y; Matsuda K; Sano K; Mita A; Ohno Y; Urata K; Ikegami T; Miwa S; Miyagawa S
    Pathology; 2011 Feb; 43(2):156-60. PubMed ID: 21233678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.